Patents Assigned to Kaohsiung Medical University
  • Auto-developing and regularly-weighted protein molecular weight marker kit and method for preparing the same
    Patent number: 8791240
    Abstract: The present invention provides an auto-developing and regularly-weighted protein molecular weight marker kit, comprising: (a) a plurality of recombinant proteins having formula (I), (B)m-A-(C)n??(I), wherein A is a polypeptide of SEQ ID NO: 1, B and C are independently any mutually identical or different polypeptides with the value of molecular weight being a multiple of 5, and m and n is independently 0 or any integer larger than 0; and (b) one or more solvents for stabilizing the recombinant proteins. The present invention also provides a method for preparing the auto-developing and regularly-weighted protein molecular weight marker kit.
    Type: Grant
    Filed: February 22, 2012
    Date of Patent: July 29, 2014
    Assignee: Kaohsiung Medical University
    Inventors: Tian-Lu Cheng, Chiu-Min Cheng
  • COMPOSITION FOR TREATING ATHEROSCLEROSIS AND A PREPARATION METHOD THEREOF
    Publication number: 20140194474
    Abstract: Disclosed are a composition for preventing and treating atherosclerosis which includes chalcone compound. In particular, the chalcone compound bound with 2-hydroxyl in ring A and 4?-methyoxy in ring B has versatile therapeutic potentials on anti-atherosclerosis by acting as PPAR? inducer, p44/42 MAPK inhibitor and cell cycle blocker and does not show toxicity to human aortic smooth muscle cells (HASMCs). In addition, the chalcone compound exhibits synergistic effect with the PPAR? ligand (rosiglitazone) to inhibit cell proliferation and the upregulation of cyclin D1, cyclin D3, interleukin-1? (IL-1?) and interleukin-6 (IL-6) induced by oxidized low density lipoprotein (Ox-LDL).
    Type: Application
    Filed: March 10, 2014
    Publication date: July 10, 2014
    Applicant: Kaohsiung Medical University
    Inventors: Yang-Chang WU, Fang-Rong Chang, Tusty-Jiuan Hsieh, Suh-Hang Juo, An-Shen Lin, Ying-Chi Du
  • Use of a pharmaceutical composition for promoting proliferation and/or migration of skin cells, and for improving wound healing in a subject
    Patent number: 8772347
    Abstract: A method for promoting proliferation and/or migration of skin cells includes providing a composition containing a compound of formula (I) below; and administrating to the skin cells the composition.
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: July 8, 2014
    Assignee: Kaohsiung Medical University
    Inventors: Hui-Min Wang, Chung-Yi Chen, Chien-Chih Chiu, Yi-Ting Chou
  • Methods for conjugating nucleic acids with small molecules
    Patent number: 8765934
    Abstract: A method for conjugating a nucleic acid with a molecule is provided. The method includes steps of (a) reacting the nucleic acid having a 5?-monophosphate with an activating agent in a first buffer to form a solution; (b) mixing an alcohol with the solution formed in the step (a) to obtain an intermediate; and (c) dissolving the intermediate in a second buffer containing an ethylenediaminetetraacetic acid (EDTA) and adding a nucleophile thereinto to react the intermediate with the nucleophile.
    Type: Grant
    Filed: July 22, 2011
    Date of Patent: July 1, 2014
    Assignee: Kaohsiung Medical University
    Inventors: Tzu-Pin Wang, Yi-Jhang Ciou
  • Ursolic acid derivative and pharmaceutical composition thereof
    Patent number: 8729055
    Abstract: Several ursolic acid derivatives and pharmaceutical compositions thereof are provided. The ursolic acid derivatives and the pharmaceutical compositions thereof have at least one of an anticancer and an anti-inflammatory effects. A method for increasing a reactive oxygen species in a cell is also provided. The method comprises a step of providing the cell with a pharmaceutical composition including an ursolic acid derivative.
    Type: Grant
    Filed: May 18, 2010
    Date of Patent: May 20, 2014
    Assignee: Kaohsiung Medical University
    Inventors: Chun-Nan Lin, Huang-Yao Tu, A-Mei Huang, Bai-Luh Wei, Kim-Hong Gan, Tzyh-Chyuan Hour, Shyh-Chyun Yang, Yeong-Shiau Pu, Shen-Jeu Won
  • Polysaccharide-grafted polyethylenimine as a gene carrier
    Patent number: 8716399
    Abstract: The present invention discloses a gene carrier and the preparation method thereof. Chondroitin sulfate (CS) is reacted with methacrylic anhydride (MA) to form chrondroitin sulfate-methacrylate (CSMA), which is further covalently bound with polyethylenimine (PEI) via the Michael addition to produce a CSMA-PEI gene carrier. The CSMA-PEI gene carrier can effectively reduce the cytotoxicity of PEI and enhance the transfection efficiency of PEI.
    Type: Grant
    Filed: November 18, 2011
    Date of Patent: May 6, 2014
    Assignee: Kaohsiung Medical University
    Inventors: Li-Fang Wang, Kuo-Hsun Sung, Yu-Lun Lo
  • Benzenoid compounds of antrodia cinnamomea, preparation and analysis method thereof
    Patent number: 8716499
    Abstract: Disclosed are a method for preparing an n-hexane extract of the fruiting body of Antrodia cinnamomea (AC), wherein the fruiting body of AC is sequentially extracted with the ethanol solution and the n-hexane solution to obtain the n-hexane extract containing at least one benzenoid compound. The amounts of 4,7-dimethoxy-5-(3-methylbut-3-en-1-ynyl)-6-methyl-1,3-benzodioxole, 4,7-dimethoxy-5-methyl-1,3-benzodioxole, antrocamphine A and the combination thereof in the at least one benzenoid compound are determined using chromatography, NMR and HPLC. In addition, the present invention is applicable on detecting the amounts of benzenoid compounds in the AC healthcare food/drug or the fruiting body of AC, and thus owns the industrial values.
    Type: Grant
    Filed: January 9, 2012
    Date of Patent: May 6, 2014
    Assignee: Kaohsiung Medical University
    Inventors: Yang-Chang Wu, Fang-Rong Chang, Mei-Chin Lu, Ying-Chi Du, Tung-Ying Wu, Yu-Ming Hsu
  • hnRNP A1 KNOCKOUT ANIMAL MODEL AND USE THEREOF
    Publication number: 20140123329
    Abstract: A nucleic acid construct comprising a genetic engineered heterogeneous nuclear ribonucleoprotein (hnRNP) A1 gene is provided. A transgenic mouse in which the expression of hnRNP A1 gene has been disrupted is also provided. The mouse is useful for studying the role of hnRNP A1 gene in normal and disease states of a developmental disorder and muscular diseases. Therefore, a method of screening a compound for potential use in prevention and/or treatment of developmental disorder and muscular diseases is further provided.
    Type: Application
    Filed: November 27, 2013
    Publication date: May 1, 2014
    Applicant: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Yung-Fu Chang, Ting-Yuan Liu, Yuh-Jyh Jong, Jan-Gowth Chang
  • METHOD OF THERAPY AND DIAGNOSIS OF ATHEROSCLEROSIS
    Publication number: 20140100129
    Abstract: There is provided a method of therapy of atherosclerosis, by providing microRNA let-7g, an analogue thereof or modified let-7g to organisms to inhibit the expression of lectin-like oxidized low density lipoprotein receptor-1 (LOX-1), and the binding of LOX-1 and oxidized low-density lipoprotein (oxLDL), so as to block the pathogenesis of atherosclerosis. Also, a method of diagnosis of atherosclerosis comprises determining the levels of microRNA let-7g in serum or plasma samples of organisms, in which the levels of microRNA let-7g is estimated in individuals with atherosclerosis as compared to individuals without atherosclerosis.
    Type: Application
    Filed: September 24, 2013
    Publication date: April 10, 2014
    Applicant: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Suh-Hang JUO, Ku-Chung CHEN, I-Chung HSIEH, Ching-Yu HU
  • Derivative of 18?-glycyrrhetinic acid apt to suppress cancer cells
    Patent number: 8686178
    Abstract: The present invention is correlated with a derivative of 18?-glycyrrhetinic acid apt to suppressing cancer cells, which is selected from a group comprising of structure I and structure II: wherein residue R1 is selected from one of CH3 and CH2C6H5, residue R2 is selected from one of COOCH3, COOCH2CH3, COOCH(CH3)2, CONHCH2CH3, CONHCH2CH2CH3, and CONHCH2(CH3)2, and residue R3 is selected from one of COOCH2CH3, COOCH(CH3)2, CONHCH2CH3, CONHCH2CH2CH3, and CONHCH2(CH3)2.
    Type: Grant
    Filed: March 14, 2012
    Date of Patent: April 1, 2014
    Assignee: Kaohsiung Medical University
    Inventors: Chun-Nan Lin, Kai-Wei Lin, A-Mei Huang, Tzyh-Chyuan Hour, Shyh-Chyun Yang, Yeong-Shiau Pu, Jan-Gowth Chang
  • Synthesis and antitumor activity of novel bis(benzylidene-benzenamine)disulfides
    Patent number: 8680155
    Abstract: Novel synthetic bis(benzylidene-benzenamine)disulfides and the preparation method are disclosed in the present invention. These compounds are afforded with the oxidizing reagent at low temperature and short time period via intra-molecular coupling reaction. In vitro experiments have been revealed that bis-disulfides are cytotoxic to cancer cells, especially human breast cancer cells MCF-7. Additionally, bis-disulfides arrest the cell cycle at sub-G1 phase and increase p38 phosphorylation to result in apoptosis. Bis-disulfides also inhibit growth of murine melanoma B16 cells but have no cytotoxicity to human fibroblasts. Bis-disulfides also can reduce murine melanoma size in the mouse model. The prepared compounds of the invention would be applicable in anticancer and anti-tumor therapies.
    Type: Grant
    Filed: July 26, 2011
    Date of Patent: March 25, 2014
    Assignee: Kaohsiung Medical University
    Inventors: Jeh-Jeng Wang, Wan-Ping Hu, Wei-Sheng Lo
  • Method for treating atherosclerosis
    Patent number: 8673875
    Abstract: The invention provides a method for treating atherosclerosis in a subject in need thereof, including administering an effective amount of microRNA-195 to the subject in need thereof. The microRNA-195 may be packaged in a pharmaceutically acceptable carrier. Moreover, the pharmaceutically acceptable carrier may includes a liposome, lipid particle or viral vector.
    Type: Grant
    Filed: December 11, 2012
    Date of Patent: March 18, 2014
    Assignee: Kaohsiung Medical University
    Inventors: Suh-Hang Hank Juo, Yung-Song Wang
  • Anti-human urothelial carcinoma of supercritical carbon dioxide extract of , and the preparation process and uses
    Patent number: 8669377
    Abstract: What is disclosed in the invention is a preparation method of a supercritical Cinnamomum subavenium extract, which is made from the material, the dried stem of C. subavenium. The extract is obtained by extracting C. subavenium which is pulverized as particles with supercritical carbon dioxide fluid. The C. subavenium extract or its active ingredient, subamolide A, can be used to inhibit the growth of human urothelial carcinoma cell lines. In addition, the C. subavenium extract (or subamolide A) is able to synergistically inhibit the growth of human urothelial carcinoma cell lines with cisplatin (CDDP) or gemcitabine (Gem). Therefore, the C. subavenium extract (or subamolide A) can be an anticancer drug alone, or forms a pharmaceutical composition with CDDP (or Gem) to treat with cancers in respect of urinary system.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: March 11, 2014
    Assignee: Kaohsiung Medical University
    Inventors: Jih-Heng Li, A-Mei Huang, Chung-Yi Chen, Pei-Jung Lien, Chiung-Hui Liu
  • Controlled release system and manufacturing method thereof
    Patent number: 8663677
    Abstract: A controlled release system and manufacturing method is provided. The method comprises providing a first aqueous solution containing a hydrophilic drug and an alkaline agent, providing an organic solution containing a hydrophobic molecule, providing a second aqueous solution containing a hydrophilic surfactant, mixing the first hydrophilic solution with the organic solution to form a first emulsion, and mixing the first emulsion with a second aqueous solution to form a second emulsion containing delayed-release microsphere.
    Type: Grant
    Filed: August 12, 2011
    Date of Patent: March 4, 2014
    Assignee: Kaohsiung Medical University
    Inventors: Yin-Chih Fu, Chih-Kuang Wang, Gwo-Jaw Wang, Mei-Ling Ho, Hui-Ting Chen, Je-Ken Chang, Cherng-Chyi Tzeng
  • Bioactivity composition of
    Patent number: 8658605
    Abstract: A series cardenolide derivatives including structure of formula I from the root of Reevesia formosana have provided. In formula (1) and (2), where R3, R5, R10 and R16 are as defined in the specification. The derivatives compounds showed potent cytotoxicity against MCF-7, NCI-H460, and HepG2 cancer cell lines.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: February 25, 2014
    Assignee: Kaohsiung Medical University
    Inventors: Ih-Sheng Chen, Hsun-Shuo Chang
  • Noninvasive cutaneous blood flow assessment as a response predictor for visible light therapy on segmental vitiligo
    Patent number: 8652061
    Abstract: Visible light is a treatment option for Segmental Vitiligo (SV), and visible light-induced repigmentation is associated normalization of sympathetic. Currently it is difficult to predict individual patient's response to visible light therapy. Therefore, the present invention uses the Laser Doppler Flowmeter to serve as a response predictor for visible light on treating SV. The present invention recruited 14 Segmental Vitiligo patients for evaluating clinical information. FirstLaser Doppler Flowmeter was used to evaluate the cutaneous blood flow of SV lesion and contralateral normal skin, and then treated them with visible light irradiate, cold-stress, rewarmed, and recorded the change of skin blood flow, finally the patients received regular visible light treatment for 3 months, and patients have a sign of repigmentation after the treatment.
    Type: Grant
    Filed: August 22, 2011
    Date of Patent: February 18, 2014
    Assignee: Kaohsiung Medical University
    Inventors: Hsin-Su Yu, Cheng-Che Lan, Wei-Tai Yu
  • SYNTHESIS OF 2-(4-AMINOPHENYL)BENZOTHIAZOLE DERIVATIVES AND USE THEREOF
    Publication number: 20140046290
    Abstract: The present invention provides a photodynamic therapy to a patient having at least one tumor comprising the steps of: administering a compound of formula 6 (wherein R1 and R2 are defined as the above) in a pharmaceutically acceptable carrier to the patient; waiting for a sufficient time to allow the administered compound to be taken up by a target tissue having the at least one tumor; and irradiating a region of the patient containing the target tissue, wherein growth of the tumor is inhibited.
    Type: Application
    Filed: October 18, 2013
    Publication date: February 13, 2014
    Applicant: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Jeh-Jeng Wang, Chao-Cheng Liao, Wan-Ping Hu, Ho-Chuan Shen
  • PREPARATION OF ANTI-PEG ANTIBODY EXPRESSING CELL AND APPLICATION THEREOF
    Publication number: 20140038208
    Abstract: The present invention provides a method for preparing an isolated eukaryotic cell which presents an anti-polyethylene glycol (PEG) antibody on a cell membrane. The present invention also provides a method for a quantitative analysis of a polyethylene glycol (PEG) by said anti-PEG antibody expressing cell. The cell-based quantitative analysis of the present prevention could sensitively quantify free PEG and PEG-modified macromolecules (proteins, nanoparticles and liposomes) as sensitive as nano-gram level.
    Type: Application
    Filed: October 18, 2013
    Publication date: February 6, 2014
    Applicant: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: TIAN-LU CHENG, STEVEN R. ROFFLER, KUO-HSIANG CHUANG, SSU-JUNG LU
  • METHOD FOR IMPROVING TETRACYCLINE-RESISTANCE OF ACINETOBACTER BAUMANNII
    Publication number: 20140018324
    Abstract: A method for improving tetracycline-resistance of A. baumannii, by providing a ginger compound combined with tetracycline to against A. baumannii infection, wherein the ginger compound comprises [6]-dehydrogingerdione, [6]-shogaol and [6]-gingerol or [10]-gingerol, [6]-shogaol and [6]-gingerol.
    Type: Application
    Filed: September 17, 2013
    Publication date: January 16, 2014
    Applicant: Kaohsiung Medical University
    Inventors: Yen-Hsu CHEN, Hui-Min WANG, Chung-Yi CHEN, Hsi-An CHEN, Wei-Ru LIN
  • Anionic cell penetrating peptide and its use for intracellular delivery
    Patent number: 8614194
    Abstract: The disclosure provides a cell penetrating peptide. The cell penetrating peptide includes an amino acid sequence of Dn, in which D represents an aspartate residue and 2?n?15.
    Type: Grant
    Filed: July 25, 2012
    Date of Patent: December 24, 2013
    Assignee: Kaohsiung Medical University
    Inventors: Hui-Ting Chen, Hsin-Fang Chang, Yan-Hsiung Wang, Chai-Lin Kao